there are three ongoing studies, including the A4 study, to evaluate the drug as a preventive strategy in healthy individuals who have high amounts of amyloid in their brains but do not have symptoms of dementia or AD.6
Solanezumab is just one of several monoclonal antibodies being studied to prevent or treat AD.
“Any intervention that could prevent cases, or even delay the onset for as little as ten years, would greatly reduce the prevalence of this disease. We are hopeful that this sort of anti-amyloid approach will begin a new era in the treatment of Alzheimer's-related brain disease,” Doody said.